Laura Ioana Mazilescu1,2,3, Sreelakshmi Kotha4, Anand Ghanekar1, Leslie Lilly5, Trevor W Reichman1, Zita Galvin5, Mark S Cattral1, Mamatha Bhat5, Ian D McGilvray1, Gonzalo Sapisochin1, Blayne Sayed1,6, Markus Selzner1, Nazia Selzner5. 1. Department of Surgery, Multi-Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada. 2. Department of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada. 3. Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 4. Department of Gastroenterology, Guy's and St Thomas Hospital, London, United Kingdom. 5. Department of Medicine, Multi-Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada. 6. Department of Surgery, The Hospital for Sick Children, Toronto, ON, Canada.
Abstract
BACKGROUND: Early allograft dysfunction (EAD) after liver transplantation has been associated with long-term reduced graft and patient survival. METHODS: In this single-center cohort study, we aimed to compare incidence, risk factors, and outcomes in liver transplant recipients who developed EAD. Patients who received donation after circulatory death (DCD) or donation after brain death (DBD) grafts between January 2007 and December 2017 were included. EAD was defined as bilirubin of ≥10 mg/dL (171 μmol/L) or an international normalized ratio of ≥1.6 on postoperative day 7 or transaminases >2000 U\L in the first-week posttransplantation as previously described. RESULTS: In our cohort of 1068 patients, incidence of EAD was 44%. EAD occurred more frequently in the DCD versus DBD group (71% versus 41%, P < 0.01). Overall, recipients who developed EAD showed a significantly lower graft and patient survival at 1, 3, and 5 y after transplantation (all P < 0.05). This was also the case for recipients of DBD grafts. However, for recipients of DCD grafts, patient and graft survival were not affected by the presence of EAD. For recipients of DBD grafts, donor age, body mass index (BMI) and gender, recipient BMI and model for end-stage liver disease score and warm and cold ischemia time were associated with EAD. For DCD recipients, donor BMI and cold ischemia time were associated with EAD. CONCLUSIONS: In our cohort study, EAD resulted in reduced long-term patient and graft survival only for DBD recipients but not for DCD recipients. Predictive markers for EAD were dependent on the donor type.
BACKGROUND: Early allograft dysfunction (EAD) after liver transplantation has been associated with long-term reduced graft and patient survival. METHODS: In this single-center cohort study, we aimed to compare incidence, risk factors, and outcomes in liver transplant recipients who developed EAD. Patients who received donation after circulatory death (DCD) or donation after brain death (DBD) grafts between January 2007 and December 2017 were included. EAD was defined as bilirubin of ≥10 mg/dL (171 μmol/L) or an international normalized ratio of ≥1.6 on postoperative day 7 or transaminases >2000 U\L in the first-week posttransplantation as previously described. RESULTS: In our cohort of 1068 patients, incidence of EAD was 44%. EAD occurred more frequently in the DCD versus DBD group (71% versus 41%, P < 0.01). Overall, recipients who developed EAD showed a significantly lower graft and patient survival at 1, 3, and 5 y after transplantation (all P < 0.05). This was also the case for recipients of DBD grafts. However, for recipients of DCD grafts, patient and graft survival were not affected by the presence of EAD. For recipients of DBD grafts, donor age, body mass index (BMI) and gender, recipient BMI and model for end-stage liver disease score and warm and cold ischemia time were associated with EAD. For DCD recipients, donor BMI and cold ischemia time were associated with EAD. CONCLUSIONS: In our cohort study, EAD resulted in reduced long-term patient and graft survival only for DBD recipients but not for DCD recipients. Predictive markers for EAD were dependent on the donor type.
Authors: Kim M Olthoff; Laura Kulik; Benjamin Samstein; Mary Kaminski; Michael Abecassis; Jean Emond; Abraham Shaked; Jason D Christie Journal: Liver Transpl Date: 2010-08 Impact factor: 5.799
Authors: Dieter P Hoyer; Andreas Paul; Anja Gallinat; Ernesto P Molmenti; Renate Reinhardt; Thomas Minor; Fuat H Saner; Ali Canbay; Jürgen W Treckmann; Georgios C Sotiropoulos; Zoltan Mathé Journal: Liver Int Date: 2014-01-24 Impact factor: 5.828
Authors: Kris P Croome; William Wall; Douglas Quan; Sai Vangala; Vivian McAlister; Paul Marotta; Roberto Hernandez-Alejandro Journal: Hepatobiliary Pancreat Dis Int Date: 2012-08-15
Authors: K Hashimoto; B Eghtesad; G Gunasekaran; M Fujiki; T D Uso; C Quintini; F N Aucejo; D M Kelly; C G Winans; D P Vogt; B M Parker; S A Irefin; C M Miller; J J Fung Journal: Am J Transplant Date: 2010-12 Impact factor: 8.086
Authors: David D Lee; Amandeep Singh; Justin M Burns; Dana K Perry; Justin H Nguyen; C Burcin Taner Journal: Liver Transpl Date: 2014-12 Impact factor: 5.799
Authors: Dagmar Kollmann; Gonzalo Sapisochin; Nicolas Goldaracena; Bettina E Hansen; Ramraj Rajakumar; Nazia Selzner; Mamatha Bhat; Stuart McCluskey; Mark S Cattral; Paul D Greig; Les Lilly; Ian D McGilvray; Anand Ghanekar; David R Grant; Markus Selzner Journal: Liver Transpl Date: 2018-05-14 Impact factor: 5.799
Authors: Stephanie Ohara; Elizabeth Macdonough; Lena Egbert; Abigail Brooks; Blanca Lizaola-Mayo; Amit K Mathur; Bashar Aqel; Kunam S Reddy; Caroline C Jadlowiec Journal: Medicina (Kaunas) Date: 2022-06-17 Impact factor: 2.948